BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AEterna Zentaris (AEZS): Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting


11/26/2012 9:35:44 AM

div class="xn-content">

QUÉBEC CITY, Nov. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that final Phase 2 data for perifosine, its oral AKT inhibitor, combined with sorafenib in patients with relapsed/refractory lymphomas, will be presented at the upcoming American Society of Hematology ("ASH") annual meeting in Atlanta, Georgia, December 8-11, 2012. Data will be disclosed during a poster presentation by Anna Guidetti, MD, of the Fondazione IRCCS Instituto Nazionale Tumori, Milan, Italy.

Abstract #3679: "Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase 2 Trial", A Guidetti, S. Viviani, A. Marchiano, A. Dodero, L. Farina, S.L. Locatelli, D. Russo, P. Bulian, R. Sorasio, M. Di Nicola, L. Giordano, P. Corradini, A.M. Gianni, C. Carlo-Stella.
Poster Session #624: "Lymphoma-Therapy with Biologic Agents, Excluding Pre-Clinical Models: Poster III"
Date & Time: Monday, December 10, 2012, from 6 pm to 8 pm (Eastern)
Venue: Georgia World Congress Center, Hall B1-B2, Level 1, Building B

About Perifosine

Perifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. It has been granted orphan drug and orphan medicinal product designations for multiple myeloma ("MM") from the FDA and the European Medicines Agency ("EMA"), respectively. Perifosine has also received Fast Track designation from the FDA. The ongoing Phase 3 trial in MM is conducted under a Special Protocol Assessment from the FDA and a positive Scientific Advice from the EMA, with positive results from this trial expected to be sufficient for registration in the US and Europe. Perifosine is also being explored in combination therapy and in monotherapy in other cancer indications. Aeterna Zentaris holds worldwide rights to perifosine except for Japan, Korea and MENA (Middle East and North Africa) region, where licensing rights have been granted to Yakult Honsha, Handok and Hikma Pharmaceuticals respectively.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->